which is why surely subjective / personal opinion by FDA as opposed to feedbcak based on written guidelines and framework around labelling and insx is worthy of appeal at least...
esp since patient studies had passed the test and shown no issues based on existing, mind you, 6th version , insx.
smells of corruption to me, typical FDA
Ann: Presentation- FDA Letter Requires Patient Instruction Update, page-54
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.010(2.70%) |
Mkt cap ! $687.8M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 38.0¢ | 36.5¢ | $1.324M | 3.541M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4056 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 653729 | 17 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |